CN106795147B - 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法 - Google Patents

作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法 Download PDF

Info

Publication number
CN106795147B
CN106795147B CN201580054674.2A CN201580054674A CN106795147B CN 106795147 B CN106795147 B CN 106795147B CN 201580054674 A CN201580054674 A CN 201580054674A CN 106795147 B CN106795147 B CN 106795147B
Authority
CN
China
Prior art keywords
amino
methyl
thia
azabicyclo
hept
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580054674.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN106795147A (zh
Inventor
J·R·艾伦
A·阿梅加兹
M·P·布尔博
J·A·布朗
J·J·陈
Y·程
M·J·弗罗恩
A·古斯曼-佩雷斯
P·E·哈林顿
L·刘
Q·刘
J·D·罗
V·V·马
J.R.曼宁
A·E·米纳蒂
T·T·阮
N·尼什穆拉
M·H·诺尔曼
L·H·佩图斯
A·J·皮克雷尔
W·钱
S·伦菲尔特
R·M·扎萨
A·C·西格蒙
M·M·斯特奇
R.D.怀特
Q·薛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN106795147A publication Critical patent/CN106795147A/zh
Application granted granted Critical
Publication of CN106795147B publication Critical patent/CN106795147B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
    • C07D279/08—1,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201580054674.2A 2014-08-08 2015-08-05 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法 Active CN106795147B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462035269P 2014-08-08 2014-08-08
US62/035269 2014-08-08
PCT/US2015/043868 WO2016022724A1 (en) 2014-08-08 2015-08-05 Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use

Publications (2)

Publication Number Publication Date
CN106795147A CN106795147A (zh) 2017-05-31
CN106795147B true CN106795147B (zh) 2020-09-22

Family

ID=54150645

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580054674.2A Active CN106795147B (zh) 2014-08-08 2015-08-05 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法

Country Status (12)

Country Link
US (2) US9550762B2 (enExample)
EP (1) EP3177618A1 (enExample)
JP (1) JP6576433B2 (enExample)
CN (1) CN106795147B (enExample)
AR (1) AR101483A1 (enExample)
AU (1) AU2015301028B2 (enExample)
CA (1) CA2957544C (enExample)
JO (1) JO3569B1 (enExample)
MX (1) MX381482B (enExample)
TW (1) TWI614250B (enExample)
UY (1) UY36263A (enExample)
WO (1) WO2016022724A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6374889B2 (ja) 2013-03-08 2018-08-15 アムジエン・インコーポレーテツド β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合１，３−オキサジン−２−アミン化合物、及び使用方法
US9550762B2 (en) 2014-08-08 2017-01-24 Amgen, Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
WO2017024180A1 (en) 2015-08-06 2017-02-09 Amgen Inc. Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
MA52722A (fr) 2016-12-15 2021-04-14 Amgen Inc Dérivés d'oxazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
MA54101A (fr) 2016-12-15 2021-10-27 Amgen Inc Dérivés de thiazine et d'oxazine bicycliques en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
EP3555086B1 (en) 2016-12-15 2021-09-01 Amgen Inc. 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use
MX386618B (es) 2016-12-15 2025-03-19 Amgen Inc Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso.
MX388697B (es) 2016-12-15 2025-03-20 Amgen Inc Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
CN113087669B (zh) * 2019-12-23 2023-11-17 南京药石科技股份有限公司 一种4-氰基-5-溴嘧啶的制备方法
CN115684413A (zh) * 2022-11-01 2023-02-03 重庆市涪陵食品药品检验所 一种硫酸羟氯喹中硫酸二甲酯和硫酸二乙酯的检测方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102119161A (zh) * 2008-06-13 2011-07-06 盐野义制药株式会社 具有β分泌酶抑制作用的含硫杂环衍生物
EP2514747A1 (en) * 2009-12-09 2012-10-24 Shionogi&Co., Ltd. Substituted aminothiazine derivative
CN103596569A (zh) * 2011-01-13 2014-02-19 诺瓦提斯公司 用于治疗代谢障碍的bace-2抑制剂
CN103649082A (zh) * 2011-04-26 2014-03-19 盐野义制药株式会社 吡啶衍生物和含有该吡啶衍生物的bace1抑制剂
CN103649083A (zh) * 2011-07-06 2014-03-19 霍夫曼-拉罗奇有限公司 作为bace1和/或bace2抑制剂的环丙基-稠合-1,3-硫氮杂*类

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
SI9300303A (en) 1993-06-08 1994-12-31 Krka Tovarna Zdravil Process for isolation of hypolipemic effective substance
JPH11507538A (ja) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US20040234976A1 (en) 1998-09-24 2004-11-25 Gurney Mark E. Alzheimer's disease secretase, app substrates therefor, and uses therefor
NZ510708A (en) 1998-09-24 2003-12-19 Upjohn Co Alzheimer's disease and Asp1 and Asp2 cleaving APP site (beta secretase)
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
SG163508A1 (en) 2003-12-15 2010-08-30 Schering Corp Heterocyclic aspartyl protease inhibitors
US20090264415A2 (en) 2004-12-30 2009-10-22 Steven De Jonghe Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
CN101346357B (zh) 2005-10-25 2014-04-02 盐野义制药株式会社 氨基二氢噻嗪衍生物
EP2689780A1 (en) * 2007-04-24 2014-01-29 Shionogi & Co., Ltd. Intermediates for aminodihydrothiazine derivatives substituted with a cyclic group
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
CN101815712A (zh) 2007-08-01 2010-08-25 辉瑞有限公司 吡唑化合物及其作为raf抑制剂的用途
BRPI0906962B8 (pt) 2008-01-18 2021-05-25 Eisai R&D Man Co Ltd composto de aminodiidrotiazina fundido
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
WO2010013302A1 (ja) 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
WO2010013794A1 (en) 2008-07-28 2010-02-04 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
US8461160B2 (en) 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
US8188079B2 (en) 2009-08-19 2012-05-29 Hoffman-La Roche Inc. 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
US20110065695A1 (en) 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
CN102686584A (zh) 2009-11-13 2012-09-19 盐野义制药株式会社 具有氨基连接基的氨基噻嗪或氨基噁嗪衍生物
WO2011071057A1 (ja) 2009-12-09 2011-06-16 塩野義製薬株式会社 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物
US7964594B1 (en) 2009-12-10 2011-06-21 Hoffmann-La Roche Inc. Amino oxazine derivatives
US20120245155A1 (en) 2009-12-11 2012-09-27 Shionogi & Co., Ltd. Fused heterocyclic compound having amino group
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
KR20120104570A (ko) 2009-12-11 2012-09-21 시오노기세야쿠 가부시키가이샤 옥사진 유도체
JP5759469B2 (ja) 2010-09-24 2015-08-05 株式会社クラレ ペースト及びその塗膜を電解質膜や電極膜とする高分子トランスデューサ
KR20140051822A (ko) 2011-01-12 2014-05-02 노파르티스 아게 옥사진 유도체 및 신경계 장애의 치료에서의 그의 용도
US8404680B2 (en) 2011-02-08 2013-03-26 Hoffmann-La Roche Inc. N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8754075B2 (en) 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
CN103608345A (zh) 2011-04-26 2014-02-26 盐野义制药株式会社 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂
EP2517898A1 (de) 2011-04-29 2012-10-31 Lanxess Deutschland GmbH Kieselsäurehaltige Kautschukmischungen mit schwefelhaltigen Additiven
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
US8604024B2 (en) 2011-05-24 2013-12-10 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
WO2012162334A1 (en) 2011-05-24 2012-11-29 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
US9079919B2 (en) 2011-05-27 2015-07-14 Hoffmann-La Roche Inc. Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors
AR086653A1 (es) 2011-06-03 2014-01-15 Bristol Myers Squibb Co COMPUESTOS PARA LA REDUCCION DE PRODUCCION DE b-AMILOIDE
JP2012250933A (ja) 2011-06-03 2012-12-20 Shionogi & Co Ltd オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物
AU2012266544A1 (en) 2011-06-07 2013-11-21 F. Hoffmann-La Roche Ag Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors
MX2013014007A (es) 2011-06-07 2014-03-12 Hoffmann La Roche [1,3] oxazinas.
US9181236B2 (en) 2011-08-22 2015-11-10 Merck Sharp & Dohme Corp. 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
WO2013030713A1 (en) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
US20130073953A1 (en) 2011-09-21 2013-03-21 Timothy Onyenobi News headline screenshot viewing system
EP2766358B1 (en) 2011-10-13 2016-06-22 Novartis AG Novel oxazine derivatives and their use in the treatment of disease
US9133129B2 (en) 2011-10-24 2015-09-15 Takeda Pharmaceutical Company Limited Bicyclic compound
PE20142376A1 (es) 2012-01-26 2015-01-17 Hoffmann La Roche Fluormetil-5,6-dihidro-4h-[1,3]oxazinas
JP2015514073A (ja) 2012-03-20 2015-05-18 エラン ファーマシューティカルズ， リミテッド・ライアビリティ・カンパニー スピロ環式ジヒドロ−チアジンおよびジヒドロ−オキサジンｂａｃｅ阻害剤、ならびにその組成物および使用
DE102012005803A1 (de) 2012-03-21 2013-09-26 Wacker Neuson Produktion GmbH & Co. KG Bohr-und/oder Schlaghammer mit belastungsabhängiger Anpassung der Schlagzahl
JP6110937B2 (ja) 2012-05-04 2017-04-05 ファイザー・インク ＡＰＰ、ＢＡＣＥ１、およびＢＡＣＥ２の阻害剤としての複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2013182638A1 (en) 2012-06-08 2013-12-12 H. Lundbeck A/S 2 -aminothiazinylheteroaryls as bace1 inhibitors for the treatment alzheimer's disease
KR20150023450A (ko) 2012-06-26 2015-03-05 에프. 호프만-라 로슈 아게 Bace1 억제제로서의 다이플루오로-헥사하이드로-사이클로펜타옥사진일 및 다이플루오로-헥사하이드로-벤조옥사진일
GB201212871D0 (en) 2012-07-20 2012-09-05 Eisai Ltd Novel compounds
CA2882389A1 (en) 2012-09-20 2014-03-27 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014059185A1 (en) * 2012-10-12 2014-04-17 Amgen Inc. Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
WO2014062549A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2908824B1 (en) 2012-10-17 2018-05-02 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2014065434A1 (en) * 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
HUE031764T2 (en) 2012-10-26 2017-07-28 Lilly Co Eli Tetrahydropyrrolothiazine derivatives as BACE inhibitors
EP2931284B1 (en) 2012-12-14 2017-08-23 Merck Sharp & Dohme Corp. Bace inhibitors of iminothiadiazine dioxides
CA2893333C (en) 2012-12-19 2017-10-24 Pfizer Inc. Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2935256B1 (en) 2012-12-19 2018-01-24 Bristol-Myers Squibb Company 4,6-diarylaminothiazines as bace1 inhibitors and their use for the reduction of beta-amyloid production
AU2013363151A1 (en) 2012-12-20 2015-06-04 Merck Sharp & Dohme Corp. C5, C6 oxacyclic-fused iminothiazine dioxide compounds as BACE inhibitors
WO2014099788A1 (en) 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. C5-spiro iminothiadiazine dioxides as bace inhibitors
KR20150109429A (ko) 2013-01-22 2015-10-01 시에나 바이오테크 에스.피.에이. Bace1 억제제로서의 플루오로-[1,3]옥사진
JP6389830B2 (ja) 2013-03-01 2018-09-12 アムジエン・インコーポレーテツド ベータ−セクレターゼ阻害剤としてのパーフルオロ化５，６−ジヒドロ−４ｈ−１，３−オキサジン−２−アミン化合物および使用方法
JP6374889B2 (ja) 2013-03-08 2018-08-15 アムジエン・インコーポレーテツド β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合１，３−オキサジン−２−アミン化合物、及び使用方法
AU2014253275B2 (en) 2013-04-11 2018-10-18 F. Hoffmann-La Roche Ag BACE1 inhibitors
MX2015014728A (es) 2013-04-26 2016-03-07 Hoffmann La Roche Sintesis de inhibidores de beta secretasa (bace).
TW201623295A (zh) 2014-04-11 2016-07-01 塩野義製藥股份有限公司 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物
WO2016001266A1 (en) 2014-07-04 2016-01-07 F. Hoffmann-La Roche Ag Fluoro-[1,3]oxazines as bace1 inhibitors
US9550762B2 (en) 2014-08-08 2017-01-24 Amgen, Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102119161A (zh) * 2008-06-13 2011-07-06 盐野义制药株式会社 具有β分泌酶抑制作用的含硫杂环衍生物
EP2514747A1 (en) * 2009-12-09 2012-10-24 Shionogi&Co., Ltd. Substituted aminothiazine derivative
CN103596569A (zh) * 2011-01-13 2014-02-19 诺瓦提斯公司 用于治疗代谢障碍的bace-2抑制剂
CN103649082A (zh) * 2011-04-26 2014-03-19 盐野义制药株式会社 吡啶衍生物和含有该吡啶衍生物的bace1抑制剂
CN103649083A (zh) * 2011-07-06 2014-03-19 霍夫曼-拉罗奇有限公司 作为bace1和/或bace2抑制剂的环丙基-稠合-1,3-硫氮杂*类

Also Published As

Publication number Publication date
CN106795147A (zh) 2017-05-31
JO3569B1 (ar) 2020-07-05
CA2957544C (en) 2023-01-24
JP6576433B2 (ja) 2019-09-18
AU2015301028A1 (en) 2017-03-09
EP3177618A1 (en) 2017-06-14
UY36263A (es) 2016-02-29
JP2017523223A (ja) 2017-08-17
US20160046618A1 (en) 2016-02-18
CA2957544A1 (en) 2016-02-11
TW201619154A (zh) 2016-06-01
AU2015301028B2 (en) 2019-09-26
US9550762B2 (en) 2017-01-24
MX381482B (es) 2025-03-12
AR101483A1 (es) 2016-12-21
MX2017001794A (es) 2017-06-29
WO2016022724A1 (en) 2016-02-11
TWI614250B (zh) 2018-02-11
US20170267673A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
CN106795147B (zh) 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法
US9085576B2 (en) Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
CN109195965B (zh) Wdr5蛋白质-蛋白质结合的抑制剂
CN105492433B (zh) 6-(5-羟基-1h-吡唑-1-基)烟碱酰胺衍生物和其作为phd抑制剂的用途
US10246429B2 (en) Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
JP2023524018A (ja) Ｉｌ－１７の調節因子としてのイミダゾリダジン
TW201446758A (zh) 作爲β－分泌酶抑制劑的全氟化５，６－二氫－４Ｈ－１，３－□－２－胺化合物及其用途
CN113710656A (zh) 作为法尼醇x受体调节剂的经取代的双环化合物
WO2014146493A1 (en) Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
CN113490668A (zh) 用于治疗与apj受体活性有关的疾病的化合物和组合物
CN113677659A (zh) 可用作类法尼醇x受体调节剂的经取代的酰胺化合物
HK40097687A (zh) 用於治疗癌症的2-杂芳基-3-氧代-2 ,3-二氢哒嗪-4-甲酰胺
HK40098354A (zh) 用於治疗癌症的2-杂芳基-3-氧代-2，3-二氢哒嗪-4-甲酰胺
HK40109889A (zh) 哌啶基吲哚衍生物、其制备方法和医药用途
HK40061670A (en) Compounds and compositions for treating conditions associated with apj receptor activity
HK40097906A (zh) 化合物、组合物和方法
HK40046970B (zh) 新型杂原子芳香族酰胺衍生物以及含有其的药剂
TW202607005A (zh) 用於治療與apj受體活性相關的病狀的化合物及組成物
HK40061670B (zh) 用於治疗与apj受体活性有关的疾病的化合物和组合物
HK40008443A (en) Imidazopyrrolopyridine as inhibitors of the jak family of kinases
HK40003047A (en) 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Allen Jennifer R

Inventor after: L *liu

Inventor after: Q *liu

Inventor after: J D Rowe

Inventor after: Ma Vu Van

Inventor after: J.R. Manning

Inventor after: A - E - carminati

Inventor after: Cox Kenneth A.

Inventor after: N, what Moora

Inventor after: Germain Julie

Inventor after: Pettus Liping H.

Inventor after: Amegadzie Albert

Inventor after: A J Peake ray

Inventor after: W *qian

Inventor after: S Glenn Feierte

Inventor after: Rzasa Robert M.

Inventor after: A - C - Sigmund

Inventor after: M - M - Sterchi

Inventor after: R.D. White

Inventor after: Q *xue

Inventor after: Bourbeau Matthew P.

Inventor after: Brown Julien Alistair

Inventor after: Chen Jrjyan Jerry

Inventor after: Y *cheng

Inventor after: M J froyen

Inventor after: Guzman-Perez Angel

Inventor after: P E Harrington

Inventor before: Allen Jennifer R

Inventor before: L .liu

Inventor before: Q .liu

Inventor before: Eksterowicz John

Inventor before: V.V. horse

Inventor before: J. Manning

Inventor before: A.E. carminati

Inventor before: Nguyen Thiep T.

Inventor before: N., what Moora

Inventor before: Germain Julie

Inventor before: Pettus Liping H.

Inventor before: Ah Mui gaz A.

Inventor before: A J Peake ray

Inventor before: W *qian

Inventor before: S Glenn Feierte

Inventor before: Rzasa Robert M.

Inventor before: A - C - Sigmund

Inventor before: M - M - Sterchi

Inventor before: WHITE RHONDA

Inventor before: Q *xue

Inventor before: M.P. Boer

Inventor before: Brown Jeff A

Inventor before: Chen Jian J

Inventor before: Y .cheng

Inventor before: Frohn Michael J

Inventor before: A. - Peres Guzman

Inventor before: P.E. Harrington

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant